Biopharma patient advocates, innovators, and investors continue to urge Congress to fix the proposed Build Back Better (BBB) legislation to improve patient Rx affordability and preserve biopharma innovation.

The omission of assumptions about genericization means that CEAs may misrepresent the long run opportunity costs for drugs. The field needs clearer guidance for when CEAs should account for genericization, and for the inclusion of other price dynamics that might influence a drug’s cost-effectiveness.

Investors, economists, academics, and industry executives urge reforms to lower out-of-pocket costs. Price controls, they warn, could cease biopharma investment and prevent future cures.

Medicines help us feel better, but there are so many other things that make medicines valuable. Learn about the many benefits of medicines and the ways that insurers overlook their value to all of us.

This slide deck contains a powerful visual illustration of the biotech industry’s race to find a cure for Hepatitis C. Run through the slide deck quickly to appreciate the sheer level of hustle that won the world a cure, and then more slowly to appreciate every move in the chess game of mergers & acquisitions.